The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial
Open accessAbstract
Background: B-cell depletion with rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable responses. We hypothesized that high B-cell activating factor (BAFF) levels after rituximab can cause disease flares, thereby limiting its effectiveness. Objective: To obtain preliminary evidence for efficacy of the anti-BAFF therapeutic belimumab after rituximab in SLE. Design: Phase 2, randomized, double-blind (patients, assessors, researchers, care providers), placebo-controlled, parallel-group, superiority trial. (ISRCTN: 47873003) Setting: England. Participants: Fifty-two patients who had SLE that was refractory to conventional treatment and whose physicians had recommended rituximab therapy were recruited between 2 February 2017 and 28 March 2019. Intervention: Participants were treated with rituximab and 4 to 8 weeks later were randomly assigned (1:1) to receive intravenous belimumab or placebo for 52 weeks. Measurements: The prespecified primary end point was serum IgG anti–double-stranded DNA (anti-dsDNA) antibody levels at 52 weeks. Secondary outcomes included incidence of disease flares and adverse events. Results: At 52 weeks, IgG anti-dsDNA antibody levels were lower in patients treated with belimumab compared with placebo (geometric mean, 47 [95% CI, 25 to 88] vs. 103 [CI, 49 to 213] IU/mL; 70% greater reduction from baseline [CI, 46% to 84%]; P < 0.001). Belimumab reduced risk for severe flare (BILAG-2004 grade A) compared with placebo (hazard ratio, 0.27 [CI, 0.07 to 0.98]; log-rank P = 0.033), with 10 severe flares in the placebo group and 3 in the belimumab group. Belimumab did not increase incidence of serious adverse events. Belimumab significantly suppressed B-cell repopulation compared with placebo (geometric mean, 0.012 [CI, 0.006 to 0.014] vs. 0.037 [CI, 0.021 to 0.081] × 109/L) at 52 weeks in a subset of patients (n = 25) with available data. Limitations: Small sample size; biomarker primary end point. Conclusion: Belimumab after rituximab significantly reduced serum IgG anti-dsDNA antibody levels and reduced risk for severe flare in patients with SLE that was refractory to conventional therapy. The results suggest that this combination could be developed as a therapeutic strategy. Primary Funding Source: Versus Arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Self-citationTreatment allocation by minimisation
Altman, D. G., & Bland, J. M. (2005) · BMJ · doi:10.1136/bmj.330.7495.843 · Cited by 550 · cited 4×
“8) Previous rituximab, n (%) 8 (31) 6 (23) Previous rituximab within 2 y from screening, n (%) 3 (11) 4 (15) Concomitant immunosuppressant or prednisolone at screening and randomization, n (%) Mycophenolate 15 (58) 19 (73) Azathioprine 2 (8) 2 (8) Methotrexate 2 (8) 3 (11) Prednisolone 24 (92) 22 (85) Any concomitant…”
BackgroundMethodInfluential
Cited by
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
M. S. Barron, A., Fabre, T., & De, S. (2024) · F1000Research · doi:10.12688/f1000research.143472.1 · Cited by 8
Evaluating the performance of four anti-dsDNA antibody detection methods
Gao, X., Wu, L., Li, Y., Wang, L., Huang, Z., Zhang, J., Su, Z., & Yang, B. (2025) · Lupus · doi:10.1177/09612033251371116 · Cited by 1
Metadata
- Authors
- Shipa, M., Embleton-Thirsk, A., Parvaz, M., Santos, L. R., Muller, P., Chowdhury, K., Isenberg, D. A., Doré, C. J., Gordon, C., Ehrenstein, M. R., BEAT-LUPUS Investigators, Isenberg, D., Gordon, C., D’Cruz, D. P., Jordan, N., Parker, B., Lightstone, L., Salama, A., Pyne, D., Edwards, C. J., Griffiths, B., Vital, E. M., Rhodes, B., Yee, C.-S., Akil, M., Topham, P., Gullick, N. J., & Hamour, S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2021-12
- Volume
- 174
- Issue
- 12
- Pages
- 1647-1657
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3199432015
- Cited by
- 159
- References
- 2
- FWCI
- 15.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.